Could two extra drugs revive immunotherapy for tough lung cancers?

NCT ID NCT05013450

Completed Disease control Sponsor: Thomas Marron Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether adding two drugs, dupilumab and anakinra, to standard immunotherapy can help people with advanced non-small cell lung cancer whose cancer has stopped responding to treatment. About 33 participants will receive the combination to see if it is safe and whether it can shrink tumors. The goal is to find a new way to overcome resistance to current immunotherapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab, Anakinra, and PD-1/PD-L1 blockers (immunotherapy drugs)
What this could lead to: If it works, this could offer a new treatment option for people with advanced lung cancer whose current immunotherapy has stopped working.
What could go wrong: This is an early-phase trial with only 33 participants, so results may not apply to everyone. Adding these drugs may also increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Tisch Cancer Institute, Mount Sinai Hospital

New York, New York, 10003, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.